We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,900
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

Systemic lupus erythematosus (SLE) is a complex multifactorial autoimmune disease characterized by loss of immune tolerance and defective immune regulatory mechanisms that lead to B cell hyperactivity and the production of pathogenic autoantibodies directed against a wide range of autoantigens, and particularly nuclear antigens [Liossis et al., 1996; Yurasov et al., 2006; Mandik-Nayak et al., 2008]. In common, the complex interaction of genetic, environmental, as well as immunological factors causes the breaking of self-tolerance of the immune system and leads to development of autoimmunity. The immune system has various mechanisms at the cellular and molecular level that negatively regulate immune responses and counteract establishment of chronic and destructive immunity [Nakken et al., 2012]. A number of circulating cytokine abnormalities have been reported in SLE and recent advances have revealed new insights in cytokine regulation of autoimmune inflammatory responses [Diveu et al., 2008]. In particular, the production of Interleukin-10 (IL-10) and transforming growth factor-β1 (TGF-β1), the two main Treg cytokines that suppress the inflammatory response, has been found to be deeply deregulated in SLE patients, so they have been considered essential elements in the etiopathology of the disease.

Given the importance of cytokines in immune system regulation, these molecules are of high interest not only in the “effector phase” of autoimmune disease in which self-tolerance has already been broken, but also in the “initiation phase” of autoimmunity, in which a lasting immune response against self antigens is first generated. Recently, it has been suggested that initial susceptibility to autoimmune disease lies at least partly in the genetics of cytokine regulation, and that many genetic polymorphisms affecting cytokine patterns could alter thresholds for immune responses, resulting in pro-inflammatory presentation of self antigens
and the subsequent misdirection of adaptive immunity against self which is observed in autoimmune disease [Kariuki et al., 2010]

Genetic polymorphisms have emerged in recent years as important determinants of disease susceptibility and severity. Polymorphisms are naturally occurring DNA sequence variations, which differ from gene mutations in that they occur in the normal healthy population and have a frequency of at least 1%. Approximately 90% of DNA polymorphisms are single nucleotide polymorphisms (SNPs) due to single base substitutions. Others include insertion/deletion polymorphisms, minisatellite and microsatellite polymorphisms. Although most polymorphisms are functionally neutral, some have effects on regulation of gene expression or on the function of the coded protein. These functional polymorphisms, despite being of low penetrance, could contribute to the differences between individuals in susceptibility to and severity of disease. Many studies have examined the relationship between certain cytokine gene polymorphism, cytokine gene expression in vitro, and the susceptibility to and clinical severity of diseases [Bidwell et al., 1999; Hollegaard and Bidwell, 2006]. Some genetic polymorphisms at the promoter regions of IL-10 and TGF-β1 genes have been associated with cytokine production. Given that the production of these molecules is controlled at genetic level, functional polymorphisms in their promoters could influence the development and severity of the disease. In the present review, we summarize the information about involvement of IL-10 and TGF-β1 genetic variants on SLE appearance and clinical presentation.

2. Role of IL-10 and TGF-β1 in immune regulation and autoimmunity

2.1. IL-10

IL-10 is a pleiotropic cytokine with important immunoregulatory functions, which can be produced by both leukocytes and structural cells within tissues, being produced in particular by Tregs in vivo [Wakkach et al., 2008]. It is pivotal in inhibiting inflammation and suppresses Th1-mediated immune response through down regulation of proinflammatory cytokine secretion from both Th1 and activated macrophages [De Waal Malefyt et al., 1993; Fiorentino et al., 1998]. It also inhibits antigen presenting cells by downregulating major histocompatibility complex class II (MHC-II) and B7 expression [Ding et al., 1993]. In addition to these inhibitory actions, IL-10 promotes B-cell-mediated functions, enhancing survival, proliferation, differentiation, and antibody production [Rousset et al., 1992]. Hence, increased production of IL-10 could thus explain B cell hyperactivity and autoantibody production, two main features of the immune dysregulation in SLE. In fact, high serum levels of IL-10 have been reported in patients with SLE and they correlated positively with the disease activity [Park et al., 1998].

The role of IL-10 in the pathogenesis of lupus remains controversial. The abnormally elevated amounts of IL-10 detected in serum of patients with SLE [Houssiau et al., 1995] and the observation that anti-IL-10 therapy can down-modulate disease in such patients [Llorente and Riehaud-Patin, 2003] suggest that this cytokine may promote disease. In contrast, mouse models have suggested a preventive role for IL-10 in the pathogenesis of lupus [Yin et al., 2003].
2002]. In particular, IL-10 knockout mice were demonstrated to develop severe lupus, with earlier appearance of skin lesions, increased lymphadenopathy, more severe glomerulonephritis, and higher mortality than their IL-10-intact littermate controls [Yin et al., 2002]. Interestingly, the injection of IL-10 could prevent the occurrence of the disease in such models [Yin et al., 2002]. The authors of the study suggested that the contradictory role of IL-10 in lupus could be explained taking into account the phase of the disease. IL-10 deficiency enhanced IFN-γ production in the CD4 and CD8 lineages, and that, in turn, was associated with increased production of IgG2a anti-dsDNA antibodies, especially at the early stages of disease development. In contrast, at later phases of disease, excessive amounts of IL-10 production led to enhanced autoantibody production and subsequent formation of pathogenic autoantibody–antigen complexes [Yin et al., 2002]. However, Llorente and colleagues demonstrated that constitutive IL-10 production by monocytes and B cells in healthy members of multicase families with SLE was significantly higher than that of healthy unrelated controls, but was similar to that of SLE patients, thus suggesting that a genetically controlled high innate IL-10 production may predispose to SLE development. [Llorente et al., 1997]

2.2. TGF-β1

Recently, experimental studies have demonstrated an association between TGF-β1 and the development of autoimmunity [Aoki et al., 2005]. TGF-β1 belongs to a large family of multifunctional proteins, secreted by a variety of cell types that act as signal molecules in controlling a great number of biological processes. Like IL-10, it is a highly pleiotropic cytokine with an important role in maintaining immune homeostasis [Li et al., 2006]. There are three TGF-β isoforms in mammalian cells, TGF-β1, 2 and 3, which use similar signaling pathways and exert overlapping, albeit not identical biological functions. TGF-β1 is involved in many critical cellular processes, including cell growth, extracellular matrix formation, cell motility, hematopoiesis, apoptosis and immune function (Moustakas et al., 2002; Schuster & Krieglstein, 2002). The cells of immune system, including B, T and dendritic cells as well as macrophages, mostly produce TGF-β1, an isoform that is also found in large amounts in the plasma [Flanders and Roberts, 2001]. TGF-β1 has pronounced anti-inflammatory and immunosuppressive functions, the latter being realized by controlling the activation, proliferation, differentiation and survival of all effector immune cells [Rubtsov et al., 2007; Wahl, 1992]. Importantly, TGF-β1 inhibits maturation of dendritic cells and modulates the functions of antigen-presenting cells, reducing the macrophage production of IL-1, IL-6, and TNF-α [Fainaru et al., 2007]. However, immunosuppressive effect of TGF-β1 was most pronounced for T cells [Rubtsov et al., 2007; Li et al., 2006]. It inhibits T cell proliferation and production of IL-2, differentiation of Th1, Th2, and cytotoxic T lymphocytes (CTL). TGF-β1 suppresses IFN-γ production from Th1, NK cells and CTL, as well as their cytotoxic activity. TGF-β1 plays an essential role in the functioning and survival of regulatory T cells (Treg), and de novo generation of Foxp3+ Treg from naïve CD4+ CD25+ T lymphocytes in the periphery [Pyzik et al., 2007; Selvaraj et al., 2007; Zheng et al., 2007]. Furthermore, recent study reveals a role for TGF-β1 as effector molecule of Foxp3+ Treg cells [Li et al., 2007]. In contrast to IL-10, TGF-β1 is also an important negative regulator of B cell differentiation and proliferation, inhibiting the production of most immunoglobulin isotypes except IgA [Lebman and Edmiston, 1999].
There are strong evidences to suggest the great importance of this cytokine in the control of autoimmunity [Aoki et al., 2005]. An association between TGF-β1 and the development of autoimmunity is clearly demonstrated in studies with complete knockout of TGF-β1 in mice or genetic manipulation of its receptors in T cells. TGF-β1 knockout mice and those with impaired TGF-β1 signaling in T cells develop an autoimmune syndrome with multiple organ involvement and death [Shull et al., 1992; Dang et al., 1995; Gorelik et al., 2000; Marie et al., 2006]. This syndrome resembles SLE and Sjogren's syndrome in humans [Dang et al., 1995] and is characterized by multifocal inflammatory process affecting the heart, brain, lungs, skeletal muscle, liver, stomach, pancreas, salivary glands and other organs, lymphoproliferation, spontaneous activation of autoreactive T lymphocytes and production of autoantibodies [Dang et al., 1995; Shull et al., 1992].

3. Functional IL-10 and TGF-β1 genetic polymorphisms

3.1. IL-10 genetic polymorphisms and IL-10 production

Human IL-10 is secreted mostly by antigen-presenting cells and Treg lymphocytes subset in response to several activation stimuli. This cytokine could be also constitutively produced at low levels by immune cells, mainly monocytes, macrophages and dendritic cells. IL-10 is a non-covalent homodimer of 36 kDa with two polypeptide chains and its gene, with GeneBank accession number: X78437, is located on chromosome 1 at 1q31-q32 and a number of polymorphisms in the promoter region have been characterized. In contrast to many other cytokines, the synthesis of IL-10 is regulated by the transcription factors Sp1 and Sp3, which are constitutively expressed by different cell types [Moore et al. 2001]. It has been recently shown that c-Jun binds to a highly conserved noncoding sequences (CNS-3) in the IL10 locus, enhancing the expression of IL-10, and AP-1 signaling pathway particularly through c-Jun transcription and activity strongly affects IL-10 expression in the Th2 cells and monocytes [Wang Z et al., 2005; Dobreva et al., 2009]. Large interindividual differences in the IL-10 inducibility have been observed, which has shown to have a genetic component of over 70%. The IL-10 gene comprises 5 exons, and to date, at least 49 IL-10–associated polymorphisms have been reported, and an even larger number of polymorphisms are recorded in SNP databases (Ensemb Genome Browser, 2006). Promoter polymorphisms have been subject to the most studies, particularly with regard to possible influences on gene transcription and protein production. Three SNPs at -1082(A/G), -819(C/T), -592(C/A) upstream from the transcription start site [D’Alfonso et al., 1995; Turner et al., 1997] have been described as well as additional two microsatellite (CA)n repeats, termed IL10.G (-1.1Kb) and IL10.R (-4Kb) and located at -1151 and -3978 respectively (Eskdale and Galager, 1995; Eskdale et al., 1997).

A complete linkage disequilibrium exists between the alleles present at positions -1082, -819 and -592; so these polymorphisms occurred in tandem. These SNPs have been associated with variability in IL-10 production [Eskdale et al., 1998; Turner et al., 1998]. In particular, SNP at position -1082A/G of IL-10 gene has been associated with IL-10 production alone or in haplotypes with other distal SNPs. Turner et al., 1997 have shown that
-1082A allele is associated with lower in vitro IL-10 production by Con A-stimulated PBMC from normal subjects. In our studies, the functional effect of -1082 A/G polymorphism was demonstrated among the Bulgarian population in both healthy volunteers and in patients with sepsis (Stanilova et al., 2006). In Caucasian populations, only three haplotypes have been found (GCC, ACC and ATA), the individuals GCC/GCC being considered as genetically high IL-10 producers [Suarez et al., 2005; Suarez et al., 2003; Turner et al., 1997]. Although the functional effects of polymorphisms in IL-10 have not yet been fully elucidated, obviously that they may play a significant role in modulating susceptibility, development and clinical features of autoimmune disease and particularly SLE. The observation of increased circulating levels of IL-10 in active SLE patients which revealed positive correlation with SLEDAI and anti-double-stranded DNA (dsDNA) titer has been reported (Park et al., 1998; Hye-Young et al., 2007). Moreover, a trend toward SLE patients having hypomethylated IL-10 promoter region accompanied by greater disease activity of SLE was recently observed (Lin et al., 2012).

3.2. TGF-β1 genetic polymorphisms and plasma concentrations of TGF-β1

The TGF-β1 gene is located on chromosome 19 (q13.1-13.3) and several SNPs were described so far in promoter region, in the non-translated region (introns), in the coding region (exons), and in the 3’-UTR region of the gene. They include three polymorphisms in the promoter region (-988C/A, -800G/A, and -509C/T), two polymorphisms located in exon 1 +869T/C (codon 10) and +915G/C (codon 25), one on exon 5 +11929C/T (codon 263), and one in 3’-UTR region of the gene at position +72 [Cambien et al., 1996]. Certain inherited variants in the promoter region of the TGF-β gene (-800G/A and -509C/T) have been associated with higher cytokine circulating concentrations. The -800G/A SNP is located in a consensus cyclic AMP response element binding protein (CREB) half site and may cause reduced affinity for CREB transcription factors whose binding is important for transcription control [Grainger et al. 1999]. The -509C/T is located within a YY1 consensus binding site and -509T allele has been associated with increased TGF-β1 plasma level [Grainger et al. 1999] and reduced T-cell proliferation [Meng et al., 2005] and a study of twins estimated that the -509C/T polymorphism explained approximately 8% of the genetic variation in TGF-β1 plasma levels (Grainger et al.,1999). Two SNPs, the +868T/C SNP, and the +915G/C SNP, give rise to amino acid substitutions at positions 10 (Leu10Pro) and 25 (Arg25Pro) in the signal peptide of TGF-β1, respectively (Cambien et al.,1996; Awad et al. 1998). The +868T/C SNP was reported to influence steady-state concentrations of TGBF1 mRNA in peripheral blood mononuclear cells and serum levels of TGF-β1, and the +915G/C SNP was found to be related to TGF-β1 production in peripheral blood leukocytes (Awad et al., 1998). Another nonsynonymous SNP of TGFB1, the +11929C/T SNP (Thr398Ile) is located in exon 5 (Cambien et.al.,1996; Awad et al.1998). The 11929C/T SNP is located closely to the site where the latency-associated peptide is cleaved from the active part of the protein (Dubois et al., 1995) and therefore, this SNP may be related to the activation process of TGF-β1, as suggested previously (Cambien et al. 1996). A high degree of linkage disequilibrium was observed between pairs of the -509C/T, 868T/C, 913G/C, and 11929C/T SNPs in white populations (Cambien et al.,1996; Grainger at al. 1999).
Although immunosuppressive effects of TGF-β1 have been well established, few studies have investigated serum TGF-β1 levels in autoimmune disorders. In fact, patients with SLE have reduced TGF-β1 production by their peripheral blood lymphocytes (Oshtuka et al., 1998). Hence, reduced TGF-β1 production by immune cells might contribute to the characteristic T cell disregulation, aberrant stimulation of autoreactive B cell, and autoantibody production in SLE patients. Also, it has been reported that decreased serum levels of TGF-β1 in patients with systemic lupus are the most pronounced and constant abnormality in the cytokine levels in these patients [Becker-Merok et al., 2010]. In attempt to elucidate the importance of TGF-β1 for the development of SLE we measured serum levels of TGF-β1 in 53 patients with SLE recruited from ‘St Ivan Rilski’ University Hospital, Sofia and in 66 healthy controls [unpublished data]. Serum samples were routinely collected and stored frozen at -20°C until assayed. At the time of sampling, neither of the patients and control subjects had clinical signs or symptoms of intercurrent illness. The concentrations of activated TGF-β1 protein in the serum samples of patients and controls were measured by quantitative sandwich ELISA technique, using commercially available kits (Qantakine®, R&D systems, Abingdon, UK). Before assay, the latent TGF-β1 contained in sera was activated to the immunoreactive form using acid activation and neutralization. The results were calculated by reference to the standard curve and expressed as ng/ml. Table 1 presents the serum concentrations of TGF-β1 in patients and healthy controls.

<table>
<thead>
<tr>
<th></th>
<th>TGF-β1 concentrations (mean±SD)</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLE total (n=53)</td>
<td>8.88 ± 3.79</td>
<td></td>
</tr>
<tr>
<td>male (n=7)</td>
<td>8.57 ± 2.72</td>
<td></td>
</tr>
<tr>
<td>female (n=46)</td>
<td>8.93 ± 3.95</td>
<td>male vs female p = 0.82</td>
</tr>
<tr>
<td>Healthy controls total (n=66)</td>
<td>32.99 ± 24.84</td>
<td></td>
</tr>
<tr>
<td>male (n=13)</td>
<td>60.98 ± 31.32</td>
<td></td>
</tr>
<tr>
<td>female (n=53)</td>
<td>26.12 ± 17.34</td>
<td>male vs female p &lt;0.001</td>
</tr>
</tbody>
</table>

Table 1. TGF-β1 concentrations (ng/ml) in SLE patients and healthy controls.

Our results showed significantly lower levels of active TGF-β1 in lupus patients compared with healthy individuals (p<0.001). These data are in principal agreement with other studies [Jin et al., 2011; Lu et al., 2004]. In addition to the decreased TGF-β1 serum concentrations in SLE patients, the authors of these studies also reported an association between lower TGF-β1 and disease activity, as well as the development of organ damage [Jin et al., 2011; Lu et al., 2004]. Taken together, these observations support the role of TGF-β1 in SLE pathogenesis and modulation of disease expression. In our study, we also observed a large interindividual
variation in serum TGF-β1 levels among healthy subjects. This variation might be partly due to the possible influence of some endogenous factors, such as gender and age on the production of TGF-β1. Given this supposition, we examined TGF-β1 levels in the context of age and gender in both healthy and affected individuals. The highest levels of TGF-β1 were found in men among the healthy subjects. In SLE patients such a correlation between serum levels of TGF-β1 and gender was not observed (Table 1), which could be explained with fact, that only men individuals with genetic predisposition to lower TGF-β1 production developed SLE or down regulation of TGF-β1 by disease progress. Additionally, age was positively correlated with serum TGF-β1 in healthy controls. TGF-β1 serum levels were lower in individuals under 45 years and higher in those aged over 45 years (P<0.001) among healthy controls as shown in Figure 1. In SLE patients, there was not a relationship between age and serum TGF-β1 levels. Thus, healthy individuals showed a pattern in which serum TGF-β1 was higher in men and elder people. It seems likely that age- or gender-specific cytokine differences could play a role in the observed age- and gender-related incidence patterns observed in SLE [Petri M, 2002]. These data allow us to hypothesis that high levels of serum TGF-β1 may protect against autoimmunity in men as well as low levels of serum TGF-β1 may predispose to the onset of autoimmunity in younger individuals.

![Figure 1](https://dx.doi.org/10.5772/53799)

Figure 1. Mean (±SD) serum TGF-β1 concentrations (pg/ml) in SLE patients and healthy controls according to the age of individuals.

Nowadays, it is considered that the control of TGF-β1 production is complex, but it has been estimated that 54% of its production is under genetic control [Grainger et al., 1999]. In this regard, we analyzed the serum levels of TGF-β1 in relation to various genotypes of -509C/T polymorphism of TGFB1 in 52 healthy controls (n = 21 for CC, 15 for CT, and 16 for TT) and in 48 SLE patients (n = 17 for CC, 24 for CT, and 7 for TT). As the mean TGF-β1 levels varied significantly by case-control status (P < 0.001), patients and controls were proceeded separately for the genotype-serum levels analysis. The results are presented on Figure 2. Among healthy individuals the highest TGF-β1 concentration was detected in individuals with TT genotype (mean ± SD, 56.9 ± 28.6 ng/ml) compared to those with CC genotype (mean ± SD, 29.5 ± 21.1
ng/ml; p = 0.001) and those with CT genotype (mean ± SD, 25.7 ± 18.8; p = 0.002). Besides the level of serum TGF-β1 in patients was found to be lower than in control subjects (Figure 1), significantly higher TGF-β1 levels were observed in SLE patients having the TT genotype (mean ± SD, 9.8 ± 2.6 ng/ml) compared to patients with CC genotype (mean ± SD, 6.7 ± 2.6 ng/ml; p=0.023). Overall, individuals with TT homozygous genotype had higher serum TGF-β1 concentration in comparison to those with either CC homozygous genotype or CT heterozygous genotype.

The study of Awad and colleagues related the carriage of GG homozygous genotype in position +915 of TGFB1 to significantly higher TGF-β1 production in peripheral blood leukocytes [Awad et al., 1998]. However, Lu et al., 2004 also, analyzing the serum levels of TGF-β1 as well as the TGF-β1 production of unstimulated and stimulated peripheral blood mononuclear cells, did not observe functional correlations with TGF-β1 production and -509 and codon10 alleles. The authors raise the question whether the lower serum TGF-β1 level that cause defective immune regulation in SLE is primarily under genetic control or secondary to the influence of ongoing cellular interactions in the cytokine context. The data from our preliminary study shown that a number of factors such as age, sex, presence of disease, and allele variants of -509 C/T SNP in the gene for TGF-β1 influence the level of this cytokine in the serum. Thus, a genetically controlled low production of TGF-β1 is a predisposing factor for the loss of negative regulation found in SLE and may constitute an important component of the genetically determined susceptibility to this disease and the autoimmune events responsible for its pathogenesis, developed under appropriate environmental stimuli.

**Figure 2.** Mean (± SD) serum TGF-β1 concentrations (ng/ml) in SLE patients and healthy controls according to the genotypes of -509 C/T polymorphism of TGFB1. * p < 0.05, ** p <.01
4. Role of IL-10 and TGF-β1 genotypes as risk factor for appearance of SLE

4.1. Role of IL-10 promoter polymorphism in susceptibility and clinical manifestation of SLE

Several evidences suggest that IL-10 could be a strong candidate gene influencing SLE susceptibility. IL-10 gene has been mapped to chromosome 1q31-32, which is a susceptibility region for SLE (LOD=3.79) [Johanneson et al., 2002]. It is also homologous to a murine SLE susceptibility region [Tsao et al., 1997]. More recently, Gateva et al., 2010 performed a large-scale replication study involving 1,310 cases and 7,859 controls, and identified 21 additional candidate susceptibility loci for SLE. Among the newly identified SLE loci is IL-10. However, in spite of the considerable number of genetic studies performed, no definitive result about its involvement in SLE susceptibility was achieved. Some works showed significant associations between IL-10 microsatellites or SNPs with SLE susceptibility or with the development of certain clinical or immunological features [Rood et al., 1999; D’Alfonso et al., 2002; Schotte et al., 2004; Chen et al., 2006; Sung et al., 2006; Chong et al., 2006; Rosado et al., 2008] while other studies indicated that these polymorphisms did not appear to have any relevance in the disease [Alarcon-Riquelme et al., 1999; Van der Linden et al., 2000; Dijstelbloem et al., 2002; Guarnizo-Zuccardi et al., 2007]. The role of IL-10 genotypes has been recently reviewed by Lopez et al., 2010. The more recent association studies dealing IL-10 promoter polymorphisms for SLE susceptibility are summarized on Table 2.

With respect to microsatellite variants, different alleles of IL10.G have been reported to be associated with SLE incidence in various populations. Thus, frequency of IL10.G9 allele (21 CA repeats) was significantly decreased in European [D’Alfonso et al., 2000, D’Alfonso et al., 2002, Eskdale et al., 1997] and Mexican-American [Mehrian et al., 1998] SLE patients, whereas the long alleles IL10.G10, G11 and G13 (with a CA repeat number greater than 21) were significantly increased in Mexican-American [Mehrian et al., 1998], Italian [D’Alfonso et al., 2000, D’Alfonso et al., 2002] and British [Eskdale et al., 1997] patients respectively. On the contrary, an increase in IL10.G4 (short allele) was reported in Chinese patients [Chong et al., 2004] whereas no significant differences in IL10.G alleles were detected in other cohorts [Schotte et al., 2004, Alarcon-Riquelme et al., 1999; Johansson et al., 2002]. Recently, a large meta-analysis summarized the results focused on the role of IL-10 promoter polymorphisms for SLE susceptibility from 16 published case-control studies involving a total of 2391 SLE patients and 3483 controls (Nath et al., 2005). The results of the meta-analysis performed by Nath et al., 2005 showed a significant association between SLE and the G11 allele of IL10.G (OR=1.279, 95% CI; 1.027±1.593, P=0.028) in whole populations, and IL-10 promoter -1082G allele was associated with SLE in Asians (OR=1.358, 95% CI; 1.015±1.816, P=0.039). It has been reported that LPS-stimulated cells from individuals carriers of the IL10.G allele with 26 CA repeats presented higher IL-10 production than those from carriers of short alleles [Eskdale et al., 1998], suggesting that long alleles might be responsible for a high IL-10 production. Thus, accordingly to these data, high IL-10 producer genotypes (with more than 21 CA repeats) could be associated with SLE susceptibility, while presence of short alleles could confer a protective effect [Chen et al., 2006; D’Alfonso et al., 2002].
Polymorphisms Association SLE/contr. Population References

IL10G, IL10R  
-1082; -819; -592  
Association of IL10.G11 allele in whole populations; Association of -1082G allele with SLE in Asians  
2391/3483 Meta-analysis Nath et al., 2005

-592 A/C  
No association with susceptibility  
Association of -592C with SLE activity  
350/330 Korean Sung et al., 2005

IL10G  
Increased G9 and decreased G8 in SLE  
Association of G13 with ACLA-IgM  
Association of G8 with CNS lupus  
237/304 Taiwanese Chen et al., 2006

-1082, -819, -592  
Association of ACC/ACC with susceptibility to SLE  
195/159 Thai Hirankarn et al., 2006

-1082; -819; -592  
No association  
120/102 Colombian Guarnizo-Zuccardi et al., 2007

IL10G, IL10R  
-1082; -819; -592  
No association of microsatellites  
Increased GCC in SLE  
116/51 Spanish Rosado et al., 2008

-1082; -819; -592  
Increased GCC in SLE  
103/300 Polish Sobkowiak et al., 2009

-1082; -819; -592  
-592 A/C  
No association  
110/138 Chinese Yu et al., 2010

-1082; -819; -592  
Increased ATA haplotype in SLE  
172/215 Taiwanese Lin et al., 2010

-1082  
No association  
157/126 Bulgarian Miteva et al., 2010

Table 2. Association of IL-10 promotor polymorphisms - IL10G, IL10R, -1082G/A (rs1800896), -819C/T (rs1800871), -592A/C (rs1800872), with SLE. Association studies published after 2005 years are given only.

Conflicting results were also obtained after examining the possible association between SLE susceptibility and SNPs at -1082, -819, and -592 positions of IL-10 gene in the different populations in which they were investigated. The frequency of high IL-10 producers (carriers of -1082G allele or GCC haplotype) has been found to be increased in several works with Asian [Nath et al., 2005; Hirankarn et al., 2006] or European [Rosado et al., 2008; Sobkowiak et al., 2009] patients, although most of the studies performed in Caucasian populations did not show significant associations [Lazarus et al. 1997, Guarnizo-Zuccardi et al, 2007; Koss et al., 2000; Suárez et al., 2005; Dijstelbloem et al., 2002; Van der Linden et al., 2000; Crawley et al., 1999].

Rosado et al., 2008 found that the GCC haplotype frequency was significantly higher in Spanish patients with SLE. To assess the functional role of genotypes, they also quantified serum IL-10 levels from patients and controls and found higher serum IL-10 levels in patients. On the basis of these data, they suggest that the IL-10 promoter haplotype that produces higher levels of cytokine is associated with SLE in Spanish population. Similar are the results and final conclusion of the study performed by Sobkowiak et al., 2009; despite the higher prevalence of the GCC/GCC, GCC/ATA and ATA/ATA genotypes in SLE patients than in controls, they
observed that only GCC/GCC genotype was significant more frequent in SLE. Hence, the conclusion suggests the GCC/GCC promoter genotype may contribute to SLE incidence in Polish patients. A very recent study investigated the association between of IL-10 promoter polymorphisms (-1082, -819 and -592) with SLE in a total of 172 Taiwanese patients and 215 controls reported an association of IL-10 ATA haplotype with SLE in Taiwanese population [Lin et al., 2010]. In another Asian population, an association of ACC/ACC haplotype of IL-10 in susceptibility to SLE has been observed by Hirankarn et al., 2006.

In this regard, we investigated the role of -1082A/G promoter polymorphism of IL-10 gene as risk factor for development and clinical manifestations of SLE in Bulgarian population. Our preliminary results did not reveal a significant association of -1082 SNP in IL-10 with SLE [Miteva et al., 2010]. New data for the distribution and the frequencies of the -1082A/G alleles and genotypes among the SLE patients and healthy controls are presented on Table 3. The results of our case-control study based on 157 patients with SLE and 166 unaffected control individuals showed that the genotype distribution is consistent with those published for other Caucasian type control cohorts [Lopez et al., 2010]. We also found the prevalence of homozygous GG genotype in SLE cases (27%) compared to the controls (13%) with OR = 1.185 (95% CI = 0.58÷2.45), although the difference did not reach statistical significance (p=0.548). In addition, we observed an increased frequency of GG genotype compared to the reference AA genotype in patients with antiphospholipid synrom (APS) (27%) compared with patients without APS (14%) with OR = 2.750, 95% CI = 0.910 ÷ 8.347, p = 0.074). This suggests that carriage of a higher IL-10 producing genotype is a risk factor for antiphospholipid autoantibody production and APS appearance, thus having a modifying effect on the clinical presentation of the disease.

<table>
<thead>
<tr>
<th>rs1800896-10</th>
<th>Genotype</th>
<th>Allele</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs1040122</td>
<td>A/G</td>
<td>A</td>
</tr>
<tr>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>AA</td>
<td>56</td>
<td>186</td>
</tr>
<tr>
<td>AG</td>
<td>74</td>
<td>128</td>
</tr>
<tr>
<td>AG+AA</td>
<td>130</td>
<td>316</td>
</tr>
<tr>
<td>AG+GG</td>
<td>101</td>
<td>208</td>
</tr>
<tr>
<td>GG</td>
<td>27</td>
<td>59</td>
</tr>
<tr>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>A</td>
<td>(36%)</td>
<td>(59%)</td>
</tr>
<tr>
<td>G</td>
<td>(47%)</td>
<td>(41%)</td>
</tr>
</tbody>
</table>

In conclusion, our data suggest that the IL-10 genotype may have a role in the susceptibility and clinical manifestations of SLE in Bulgarian population.

Table 3. Genotypic and allelic frequency of gene polymorphism at position -1082 A/G in IL-10 gene in SLE patients and controls.
The presence of autoantibodies, mainly directed against nuclear antigens (ANAs), is one of the most characteristic features of SLE. The effect of IL-10 genotypes did not seem to be especially relevant, although it has been reported an increased prevalence of antibodies against several extractable nuclear antigens (anti-ENA) in patients with the allele IL-10.G9 [Eskdale, et al., 1997], and the presence of anti-Sm antibodies was found significantly overrepresented among patient carriers of G14 and G15 alleles and R2-G15 and R2-G14 haplotypes [Schotte et al., 2004]. An association of the carriage of low IL-10 producer alleles such as IL10.G13 allele with the presence of anticardiolipin IgM antibodies and IL10.G8 allele with neurological affection has been reported in Taiwanese patients with SLE [Chen et al., 2006], results very similar to the data from our study.

Considering increased circulating levels of IL-10 have been consistently reported in the sera of patients with SLE, it is possible that different cytokine production may not only influence the autoantibody production, but also the clinical presentation of the disease. However, there were no definitive data on the association of IL-10 polymorphisms and specific clinical manifestations, probably due to the heterogeneity of the disease. For instance, renal involvement has been associated with both high (GCC) [Lazarus et al., 1997, Zhu et al., 2005] and low (ATA) [Mok et al., 1999] IL-10 producer genotypes. High prevalence of neuropsychiatric [Rood et al., 1999; Chen et al. 2006] and cardiovascular disorders [Fei et al., 2004] has been reported in patients with low genetic production whereas high IL-10 production has been linked to an increased incidence of serositis, hematological disorder [Chong et al.], SLICC/ACR Damage Index [Sung et al., 2006] and presence of discoid or mucocutaneous lesions [Suárez et al., 2005; Alarcón-Riquelme et al.,1999]. This last association was supported by the increased frequency of the high producer -1082G allele observed in patients with discoid lupus erythematosus [Suárez et al., 2005; Van der Linden et al., 2000] and by the fact that cutaneous manifestations improved in SLE patients under anti IL-10 monoclonal antibody treatment [Llorente et al., 2000]. In conclusion IL-10 promoter SNPs alone have not exhibits strong association with SLE susceptibility, but their role can’t be excluded. Each polymorphism in regulatory regions of gene, may either directly influence gene expression or indirectly via tight linkage with other polymorphisms occurring elsewhere in the same or in other cytokine gene. A particular combination of SNPs on cytokine genes in individual genotype has different impacts on induced cytokine production. Miteva and Stanilova investigate the combined effect of -1082A*G in IL10 and +16974A*C in IL12B SNPs on induced cytokine production by stimulated peripheral blood mononuclear cells isolated from healthy donors (Miteva, Stanilova, 2008). Results demonstrated that the production of IL-10 from PBMC depended on both, -1082A*G in IL10 and +16974A*C in IL12B polymorphisms and the presence of high producer IL-12p40 genotype led to diminished production of IL-10 determined by -1082*G- allele of SNP in IL10. In the same vein, we suppose that individuals with genotype which combine SNPs responsible for higher production of IL-10 simultaneously with lower production of TGF-β1 should be more susceptible to SLE.
4.2. Role of TGB-β1 genetic polymorphisms in susceptibility and clinical manifestation of SLE

Regarding the association between decreased TGF-β1 serum levels and the development of autoimmunity, the mechanisms which control the concentration of TGF-β1 in plasma are under extensive investigations. The concentration of both latent complex and active TGF-β1 in plasma has been shown to be predominantly under genetic control [Grainger et al., 1999]. In light of these findings TGF-β1 gene is a functional candidate gene for genetic predisposition in systemic lupus erythematosus.

The presence of polymorphisms in the TGFB1 locus may indicate predisposition to diseases, such as systemic lupus erythematosus that have been linked here and elsewhere [Caserta et al., 2004; Lu et al., 2004] to the circulating levels of TGF-β1. To test this hypothesis, we performed a population based case-control study to investigate the association of -509C/T polymorphism of the TGFB1 gene with susceptibility to SLE [Manolova et al., 2012]. In this investigation, the change at position -509C/T in the TGFB1 gene (rs1800469) was studied using RFLP-PCR among 147 cases with SLE and 134 normal Bulgarian subjects. The genotype distribution and allele frequencies of -509C/T SNP in gene promoter of TGFB1 among SLE patients and healthy donors are presented in Table 4.

<table>
<thead>
<tr>
<th>rs1800469</th>
<th>Genotype</th>
<th>Allele</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CC</td>
<td>CT</td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>SLE (n=149)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td>(32.2%)</td>
<td>(53%)</td>
</tr>
<tr>
<td>HC (n=134)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>(35.8%)</td>
<td>(42.5%)</td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>1.318</td>
<td>1.827</td>
</tr>
<tr>
<td></td>
<td>(0.63±2.77)</td>
<td>(0.91±3.69)</td>
</tr>
<tr>
<td>p</td>
<td>0.428</td>
<td>0.068</td>
</tr>
<tr>
<td>HC (n=134)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1.386</td>
</tr>
<tr>
<td></td>
<td>ref.</td>
<td>(0.79±2.43)</td>
</tr>
<tr>
<td>p</td>
<td>0.223</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 4. Genotypic and allelic frequency of gene polymorphism at position -509 in TGFB1 gene in SLE patients and controls.
The genotype distribution for TGFB1 -509C/T polymorphism was in agreement with Hardy-Weinberg equilibrium among cases ($\chi^2=2.00; p=0.367$) and controls ($\chi^2=2.237; p=0.326$). Homozygous CC genotype was found in 32.2% of patients and 36.8% of control subjects, heterozygous CT genotype was observed in 53% of SLE patients and 42.5% of controls, homozygous TT genotype was detected in 14.8% of cases and 21.6% of controls. There were no significant differences in the genotype ($p=0.155$) and allele ($p=0.694$) frequencies of -509C/T polymorphism of the TGFB1 gene between SLE patients and controls. However, we observed a higher frequency of heterozygous CT genotype ($OR = 1.827; 95\% CI 0.91\pm3.69; p = 0.068$) and lower frequency of TT genotype ($OR = 0.759; 95\% CI: 0.36\pm1.59; p=0.428$) in SLE patients compared to healthy controls. In logistic regression analysis the presence of allele C in the genotype (CT + CC versus TT) was associated with a 1.6 times higher risk of developing systemic lupus erythematosus.

Genotype and allele frequencies of -509C/T polymorphism in TGFB1 which we established in Bulgarian population were comparable to those found in other populations. However, the available data in the literature reveal the existence of ethnic differences in frequencies of the allele variants of this polymorphic marker (Table 5). C allele had the higher representation among Europeans in French [Cambien et al., 1996], German [Wu et al., 2008] and British [Awad et al., 1998] studies with a frequency of 65 to 76 percent, while among healthy individuals from different Asian ethnicities T allele occurs more frequently or almost equally with the C allele [Amirghofran Z, 2009; Zhang et al., 2009; Chung et al., 2007]. In Bulgarian population allele C is slightly more common and was found in 57% of healthy subjects and in 59% of cases with SLE.

According to our knowledge there are only a limited number of studies aiming to evaluate the possible role of polymorphisms in the TGF-β1 gene as predisposing factors for SLE, but the results of these studies are contradictory. The polymorphisms in of -509C/T SNP in TGF-β1 have been explored in SLE only by three research teams [Lu et al., 2004; Caserta et al., 2004; Vuong et al., 2010]. In overall, the contradictory results in the literature could be explained by the genetic heterogeneity of SLE in different populations and possible sample stratification. Table 6 summarizes the association studies dealing TGF-β1 gene polymorphisms for SLE susceptibility.

### Table 5. Interethnic differences in allele frequencies of -509C/T SNP in TGFB1 in healthy controls.

<table>
<thead>
<tr>
<th>Locus</th>
<th>Allele</th>
<th>Frequency (%) among healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C</td>
<td>Bulgarian study Data from this study</td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>43</td>
</tr>
</tbody>
</table>

Table 5. Interethnic differences in allele frequencies of -509C/T SNP in TGFB1 in healthy controls.
Lu et al. conducted a case-control study involving 134 patients and 182 healthy individuals of Taiwanese origin to evaluate the association of -509C/T SNP in \( \text{TGFB1} \) with susceptibility to systemic lupus erythematosus [Lu et al., 2004]. In the same study, authors investigated also association of some others TGF\( \beta1 \) single nucleotide polymorphisms, including -988C/A, -800G/A, +869T/C (Leu10Pro), and +915 G/C (Arg25Pro) with susceptibility to SLE and shown that none of the TGF\( \beta1 \) SNPs was strongly associated with SLE in Taiwanese patients. They conclude that these polymorphisms do not represent a genetic predisposition to SLE. In another study, Schotte and colleagues investigated the +915G/C polymorphism at codon25 and did not found any association between this polymorphism and SLE in German population [Schotte et al., 2003]. In addition, authors found no association of major disease manifestations or specific autoantibodies with TGF\( \beta1 \) genotypes or alleles. The authors conclude that +915G/C polymorphism in TGF\( \beta1 \) neither significantly contributes to the disease susceptibility, nor predisposes to clinical and immunological manifestations typical of SLE. Also, there were no significant associations between several SNPs from the TGF\( \beta1 \) including -509C/T, +869T/C,
intronic G/T (rs2241715), and 3'-UTR A/G (rs6957) with SLE or with lupus nephritis in Sweden population [Vuong et al., 2010].

In contrast to these data are the results obtained by Guarnizo-Zuccardi et al., 2007 for several cytokine gene polymorphisms in Colombian patients with SLE. They analyze the relation between the +868T/C and the +915G/C SNP in TGFB1 with the development and clinical manifestations of SLE. The authors found a strong association of SLE with the TGF-β1 codon25 C allele, associated with decreased TGF-β1 production and found lower rates of higher-producing GG genotype and a higher frequency of heterozygous genotypes in this polymorphic marker in patients with SLE. As for the +868T/C polymorphism at codon10, Guarnizo-Zuccardi et al., 2007 did not observe association between SLE and codon10 when analyzing independently, but they found a significant association when the haplotypes codon10/20 were evaluated, which could be because of the linkage disequilibrium between the two SNPs. This extended genotypic analysis revealed a lower frequency of high TGF-β1 producers – haplotype 10/25 T/T-G/G in Colombian patients with SLE. Unlike the relationship of +868T/C and +915G/C SNPs of the TGFB1 gene to disease susceptibility, they found no association between clinical features of the disease and the polymorphisms studied. As opposed to this report, Wang et al., 2007 did not find an impact of +869T/C polymorphism in TGF-β1 gene on disease susceptibility in population-based case-control study involving 196 patients with SLE and 106 healthy controls in Japan. However, they found an association between +869T/C TGFB1 polymorphism and several clinical features of SLE. The carriage of TT genotype of +869T/C polymorphism which is associated with a lower serum TGF-β1 level was related to the occurrence of aseptic necrosis and higher incidence of anti-SSA/Ro antibodies in SLE patients. Consistent with the last finding, the children with the TT +869T/C genotype of TGFB1 gene have been reported to be more susceptible to anti-SSA/Ro antibody-associated congenital hear block [Clancy et al., 2003].

Systemic lupus erythematosus is a heterogeneous disease with diverse clinical manifestations that range could be due to genetic factors. In this regard, we also analyzed the effect of the -509C/T polymorphism in TGFB1 the clinical manifestations evolved in the course of the disease [Manolova et al., 2012]. The results of our study demonstrated a weak association of -509C/T polymorphism of TGFB1 with clinical manifestations of SLE. The carriage of the heterozygous genotype was associated with about 2-fold higher risk for the occurrence of hematological manifestations (OR=2.41; 95% CI: 1.10±5.32; p=0.016) and antibodies against dsDNA (OR = 2.0; 95% CI: 0.96±4.2, p = 0.045) in lupus patients, while the CC genotype is a protective factor for these events. Based on our and others data, we could assume the TGFβ1 gene polymorphisms as one of the genetic factors that explain the heterogeneity seen in SLE.

5. Conclusions

In recent years, efforts have been made to identify genes involved in the genetic predisposition and severity of SLE. During the last two decades, many of the ‘candidate’ cytokine genes
implicated in SLE development have been identified and was summarized in this review. SLE is clinically heterogeneous and genetically complex, and we expect that individual genes and cytokine patterns will be more or less important to different disease manifestations and subgroups of patients. Defining these genotype-cytokine-phenotype relationships will increase our understanding of both initial and progression disease pathogenesis.

In ours and others studies have been analyzed the association of IL-10 and TGF-β1 genetic variants with susceptibility to and outcome of SLE, showing variable results in most cases. However, it is known that the actions of cytokines may be profoundly conditioned by the presence of other cytokines, this being particularly true in the case of IL-10 and TGF-β1. New studies of particular combinations of SNPs on these cytokine genes in individual genotype and their impacts on the induced cytokine production could reveal the relation with susceptibility and clinical presentation of autoimmunity diseases.

Author details

Irena Manolova1, Mariana Ivanova2 and Spaska Stanilova3

1 Department of Health Care, Medical Faculty, Trakia University, Stara Zagora, Bulgaria
2 Clinic of Rheumatology, University Hospital, Medical University, Sofia, Bulgaria
3 Department of Molecular Biology, Immunology and Medical Genetics, Medical Faculty, Trakia University, Stara Zagora, Bulgaria

References


[33] Gateva et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009), 41(11), 1228-33.


Gene Polymorphisms of Immunoregulatory Cytokines IL-10 and TGF-β1 in Systemic Lupus Erythematosus

http://dx.doi.org/10.5772/53799


